Caplin Point Laboratories (524742) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 delivered consolidated revenue of ₹533.4 Cr, up 11.7% YoY, and PAT of ₹150.8 Cr, up 20.7% YoY, with EBITDA at ₹200.9 Cr, up 17.9% YoY, driven by strong growth in both emerging and regulated markets.

• Latin America remains the core market, with expansion into Mexico, Chile, Colombia, Brazil, and new warehouse and acquisitions in Chile and Mexico.

• US market revenue grew 36% YoY to ₹108.5 Cr, with 38 ANDAs approved, 13 under review, and robust specialty product launches.

• The company maintains a debt-free, asset-light model, funding all capex through internal accruals and focusing on sustainable profitability.

• Caplin Steriles USA reached profitability within a few quarters, launching 21-24 products, with further launches planned.

Financial highlights

• Q1 FY26 revenue reached ₹533.4 Cr, up 11.7% YoY; gross margin improved to 61.7%; EBITDA margin at 37.7%; PAT margin at 28.3%.

• PAT grew 20.7% YoY to ₹150.8 Cr; basic EPS increased 23.1% YoY to ₹20.10.

• Free cash reserves stood at ₹1,237 Cr; liquid assets at ₹2,207 Cr as of June 30, 2025.

• Cash flow from operations was ₹118 Cr, with free cash flow at ₹53 Cr after ₹65 Cr capex.

• R&D spend in FY25 was 16.5% of PAT, among the highest in the industry.

Outlook and guidance

• Management expects 14%-16% growth for the next two years, accelerating to 20%-25% from FY2028 as new geographies and products scale.

• GLP-1 and pre-filled syringe product launches planned in Latin America and US, with ramp-up dependent on regulatory approvals.

• Oncology and API facilities, backward integration, and onshoring in LatAm and US expected to support medium-term growth.